| Literature DB >> 30974872 |
Salvatore Savasta1, Alessandra Rossi2, Thomas Foiadelli3, Amelia Licari4, Anna Maria Elena Perini5, Giovanni Farello6, Alberto Verrotti7, Gian Luigi Marseglia8.
Abstract
Melkersson-Rosenthal syndrome (MRS) in children is a rare condition, clinically characterised by a triad of synchronous or metachronous symptoms: recurrent peripheral facial palsy, relapsing orofacial oedema, and a fissured tongue; the most recent review published on the topic has reported 30 published patients. The aetiology of this disease is still unclear. However, genetic factors, as well as alterations in immune functions, infections, and allergic reactions have been postulated. We report three children suffering from MRS and perform a literature review of paediatric cases. Taking into account that clinical and laboratoristical criteria for the diagnosis of MRS are lacking, this syndrome is probably underestimated, and we suggest increasing awareness of such a rare syndrome. Close multidisciplinary follow-up of these children with a team composed by paediatricians, neurologists, neuro-ophthalmologists, dermatologists, and otolaryngologists is crucial to guarantee exhaustive management and treatment success, while minimising relapses.Entities:
Keywords: Melkersson Rosenthal Syndrome; fissured tongue; peripheral facial palsy
Mesh:
Year: 2019 PMID: 30974872 PMCID: PMC6479526 DOI: 10.3390/ijerph16071289
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Right-sided deviation of the labial commissure, obliteration of the left nasolabial fold, and incomplete closure of the left eye (Patient 1).
Figure 2Fissured tongue (Patient 1).
Melkersson–Rosenthal syndrome in children and adolescents: literature review and case reports.
| Reference | Sex * | Age ** | Episodes *** | FP § | Left FP | Right FP | Orofacial Oedema | Lingua Plicata | Treatment | |
|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | Onset | |||||||||
| G.B. New, 1933 [ | F | 31 | 4 | 5 | Y | ≥1 | ≥1 | Y | NA | P |
| M | 25 | 12 | 3 | Y | 1 | 1 | Y | NA | P | |
| M | 19 | 2 | ≥2 | Y | NA | ≥1 | Y | NA | P | |
| K.A. Ekbom, 1950 [ | F | 25 | 16 | 6 | Y | 2 | 1 | Y | Y | None |
| NA | NA | 8 | 1 | Y | NA | NA | Y | Y | None | |
| M | 20 | 15 | 4 | Y | 1 | 3 | N | Y | None | |
| Ehmann, 1962 [ | NA | 22 m | NA | NA | Y | NA | NA | Y | Y | NA |
| NA | 8 | NA | NA | Y | NA | NA | Y | Y | NA | |
| R.H. Kundstadter, 1965 [ | M | 5 y 6 m | 2 y 6 m | 4 | Y | 2 | 2 | Y | N | C |
| G.A. Scott, 1968 [ | M | 8 | 6 | 2 | Y | 1 | 1 | N | Y | None |
| F | 16 | 16 | 1 | Y | 0 | 1 | N | Y | None | |
| F | 15 | NA | 8 | Y | ≥1 | ≥1 | Y | Y | None | |
| M | 10 | 10 | 3 | Y | 1 | 2 | Y | Y | None | |
| F | 12 | 12 | 1 | Y | 0 | 1 | N | Y | None | |
| M | 62 | 10 | >1 | Y | >1 | 0 | Y | Y | None | |
| D. Dylewska, 1969 [ | NA | 9 | NA | NA | NA | NA | NA | NA | NA | NA |
| P.K. Mukherjee, 1973 [ | F | 8 | ≤8 | 1 | Y | 1 | 1 | Y | Y | None |
| AIT.J. Storrs, 1975 [ | F | 16 | NA | NA | Y | NA | NA | Y | NA | C, H |
| H. Butenschon, 1976 [ | M ‡ | 10–13 | C, AB, ND | |||||||
| F †† | 5–14 | |||||||||
| B. Roseman, 1978 [ | F | 7 | NA | >1 | Y | NA | NA | Y | Y | H |
| C. Lygidakis, 1979 [ | F | 12 | 7 | 3 | Y | 2 | 1 | Y | N | None |
| M. May, 1981 [ | M | NA | ≤4 | 10 | Y | 1–9 | 1–9 | Y | Y | NA |
| J. Neuhofer, 1984 [ | F | 15 | NA | NA | Y | NA | NA | Y | Y | CF |
| V. Hridinova, 1985 [ | NA | child | NA | NA | NA | NA | NA | NA | NA | NA |
| S. Yuzuk, 1985 [ | F | 13 | NA | NA | N | 0 | 0 | Y | Y | P |
| K.M. Grundfast, 1990 [ | NA | 15 | NA | 3 | Y | 0 – 2 | 1 – 3 | Y | Y | C |
| E. Truy, 1992 [ | NA | child | NA | NA | Y | NA | NA | Y | Y | NA |
| L.T. Glickman, 1992 [ | F | 14 | NA | NA | Y | NA | NA | N | Y | None |
| M | 15 | NA | NA | NA | NA | NA | Y | NA | C | |
| W.M. Zimmer, 1992 [ | M | NA | 6 | NA | NA | NA | NA | NA | NA | C |
| M | NA | 0–10 | NA | NA | NA | NA | NA | NA | ||
| C. Bourgeois-Droin, 1993 [ | F | 10 | 10 | 2 | N | 0 | 0 | Y | Y | C, CF |
| M. Pellegrino, 1993 [ | M | 13 | NA | NA | Y | NA | NA | Y | Y | NA |
| C. Marques, 1994 [ | M | 15 | 15 | 3 | Y | NA | NA | Y | Y | C, CF |
| NA | 6 | 6 | 1 | N | 0 | 0 | Y | Y | ||
| H.A. Cohen, 1994 [ | M | 10 | NA | >1 | Y | 0 | 1 | Y | Y | NA |
| F | 10 | NA | >1 | Y | NA | NA | Y | Y | NA | |
| M | 8 | NA | >1 | Y | NA | NA | Y | N | NA | |
| M | 5 | NA | NA | Y | 1 | 0 | Y | N | NA | |
| E. Ruza Paz-Curbera, 1998 [ | M | 15 | NA | NA | N | 0 | 0 | Y | N | C, H |
| S.L. Stein, 1999 [ | F | 12 | 12 | NA | N | 0 | 0 | Y | Y | C, AB |
| M | 10 | 10 | NA | N | 0 | 0 | Y | N | ||
| P.E. Ziem, 2000 [ | F | 9 | 4 | 3 | Y | 3 | 0 | Y | N | C, AB |
| D. Salgado Alves Vilela, 2002 [ | M | 17 | ≤16 | 4 | Y | 1 | 3 | N | Y | C, ND |
| F | 23 | 14 | 6 | Y | 3 | 3 | N | Y | ||
| F | 16 | 4 | 3 | Y | 3 | 0 | Y | Y | None | |
| F | 20 | 2 | 3 | Y | 1 | 2 | Y | Y | ||
| H. Caksen, 2002 [ | NA | child | NA | >1 | Y | NA | NA | Y | Y | NA |
| I. Dodi, 2006 [ | M | 8 | NA | NA | N | 0 | 0 | Y | N | C |
| H. Hentati, 2008 [ | M | 18 | 17/18 | 2 | Y | 1 | 0 | Y | Y | C |
| H. Alp, 2009 [ | M | 10 | NA | >1 | Y | NA | NA | Y | N | NA |
| O. Ozgursoy, 2009 [ | M | 32 | 16 | 6 | Y | 2 | 3 | Y | Y | C |
| M | 21 | 12 | >1 | N | 0 | 0 | Y | Y | C | |
| S. Lourenaço, 2010 [ | M | 10 | 7 | P | N | 0 | 0 | Y | Y | NA |
| R. Liu, 2013 [ | M | 45 | 6 | >1 | Y | >1 | >1 | N | Y | C |
| M | 16 | 4 | NA | N | 0 | 0 | Y | Y | C | |
| M.K. Elias, 2013 [ | F | 16 | 10 | NA | Y | NA | NA | Y | Y | C |
| Ü. Yilmaz, 2014 [ | NA | NA | 13 | 2 | Y | NA | NA | NA | Y | NA |
| Y. Lee, 2014 [ | F | 9 | 8 | 2 | Y | 0 | 2 | Y | Y | C |
| S. Feng, 2014 [ | ||||||||||
| C.M. Rivera-Serrano, 2014 [ | M | 22 | 2 | 8 | Y | 4 | 4 | Y | N | NA |
| M | 32 | 10 | 3 | Y | 1 | 2 | Y | N | ND | |
| F | 40 | 15 | 6 | Y | 0 | 6 | Y | Y | NA | |
| F | 31 | 7 | 6 | Y | 5 | 1 | N | Y | ND | |
| S. Bohra, 2015 [ | F | 16 | 16 | 1 | Y | 1 | 0 | Y | Y | C, S |
| F. Kayhan, 2015 [ | F | 13 | 5 | 6 | Y | 0 | 6 | Y | Y | C, S |
| G. Kayabasoglu, 2015 [ | F | 17 | 10 | 6 | Y | 3 | 3 | Y | Y | C |
| A.G. Saini, 2016 [ | F | 8 | 2y6m | 6 | Y | 3 | 3 | Y | Y | C, ACV |
| S.S. Bakshi, 2016 [ | F | 9 | 7 | 2 | Y | 2 | 0 | Y | Y | C |
| Z. Chu, 2016 [ | M | 12 | 10 | >1 | Y | 0 | 1 | Y | Y | C |
| L. Bordino, 2016 [ | M | 7 | 7 | 2 | Y | 1 | 1 | Y | Y | NA |
| F | 11 | 9 | 2 | Y | 1 | 1 | N | Y | C, ACV, S | |
| J. Lalosevic, 2017 [ | F | 12 | 9 | P | N | 0 | 0 | Y | N | C, AB |
| X.G. Xu, 2017 [ | F | NA | 12 | 2 | Y | 0 | 2 | Y | Y | NA |
| C. Fantacci, 2018 [ | F | 8 | 5 | 2 | Y | 0 | 2 | Y | Y | C, ACV, IVIG, S |
| G. Psillas, 2018 [ | F | 5 | NA | N | Y | 1 | 0 | Y | Y | C |
| S. Savasta, 2018 | F | 14 | 11 | 2 | Y | 1 | 1 | Y | Y | C, ACV, S |
| F | 7 | 3 y 1 m | 4 | Y | ≥ 3 | NA | N | Y | C, S | |
| F | 9 | 18 m | 2 | Y | 0 | 2 | Y | NA | C, ACV, S | |
* Sex: F = Female, M = Male; ** age of the first episode and age of diagnosis; *** number of the episodes, including the first one; FP = Facial Palsy; Y = presence; N = absence; NA: data not available (when used for the age, NA refers to paediatric age); P = physical destruction of the involved mucocutaneous tissues (includes: boiling water local injections, external X-ray irradiation, surgical removal); C = corticosteroids; CF = clofazimine; H = antihistaminic drugs; AB = antibiotics; ND = surgical nerve decompression; S = symptomatic therapy (including analgesics, vitamins—B12 supplementation in particular—physiotherapy, and the prevention of complications, such as ocular infections with antibiotic eye drops); ACV = acyclovir; IVIG = intravenous immunoglobulins; ¶: Melkersson–Rosenthal’s symptoms described without a definite diagnosis (in 1933 the triad had not been described yet); † Other three cases reported in the article; ‡ four cases between 10 and 13 years; †† 11 cases between 5 and 14 years; ¶¶ Other two cases reported in the article, both diagnosed before 10 years; ‡† 18 Cases (8 M; 10 F) with first manifestation at under nine years old.
Figure 3Age distribution at diagnosis.
Figure 4Age distribution at first episode.